Background The objective of this study is to report the costs of Chagas disease in Colombia, in terms of vector disease control programmes and the costs of providing care to chronic Chagas disease patients with cardiomyopathy. Methods Data were collected from Colombia in 2004. A retrospective review of costs for vector control programmes carried out in rural areas included 3,084 houses surveyed for infestation with triatomine bugs and 3,305 houses sprayed with insecticide. A total of 63 patient records from 3 different hospitals were selected for a retrospective review of resource use. Consensus methodology with local experts was used to estimate care seeking behaviour and to complement observed data on utilisation. Findings The mean cost per house per entomological survey was $4.4 (in US$ of 2004), whereas the mean cost of spraying a house with insecticide was $27. The main cost driver of spraying was the price of the insecticide, which varied greatly. Treatment of a chronic Chagas disease patient costs between $46.4 and $7,981 per year in Colombia, depending on severity and the level of care used. Combining cost and utilisation estimates the expected cost of treatment per patient-year is $1,028, whereas lifetime costs averaged $11,619 per patient. Chronic Chagas disease patients have limited access to healthcare, with an estimated 22% of patients never seeking care. Conclusion Chagas disease is a preventable condition that affects mostly poor populations living in rural areas. The mean costs of surveying houses for infestation and spraying infested houses were low in comparison to other studies and in line with treatment costs. Care seeking behaviour and the type of insurance affiliation seem to play a role in the facilities and type of care that patients use, thus raising concerns about equitable access to care. Preventing Chagas disease in Colombia would be cost-effective and could contribute to prevent inequalities in health and healthcare.
References
[1]
Guhl F, Angulo V, Restrepo M, Nicholls S, Montoya R (2003) Estado Del Arte de la Enfermedad de Chagas en Colombia y estrategias de Control. Biomédica 23(suplemento 1): 31–37.
[2]
WHO (2002) Control of Chagas Disease, Second report of the WHO Expert Committee. WHO Technical Report Series 905. Geneva.
[3]
Moncayo A (2003) Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Memorias do Instituto Oswaldo Cruz 98(5): 577–91. doi: 10.1590/S0074-02762003000500001
[4]
Zerba EN, Wallace G, Picollo MI, Casabé N, de Licastro S, et al. (1997) Evaluation of beta-cypermethrin for the control of Triatoma infestans. Revista Panamericana de Salud Publica 1: 133–137. doi: 10.1590/S1020-49891997000200007
[5]
Wastavino GR, Cabrera-Bravo M, García De La Torre G, Vences-Blanco M, Hernández AR, et al. (2004) Insecticide and community interventions to control Triatoma dimidiata in localities of the State of Veracruz, Mexico. Memorias do Instituto Oswaldo Cruz 99: 433–437. doi: /S0074-02762004000400015
[6]
Ramsey JM, Cruz-Celis A, Salgado L, Espinosa L, Ordo？ez R, et al. (2003) Efficacy of pyrethroid insecticides against domestic and peridomestic populations of Triatoma pallidipennis and Triatoma berberi (Reduviidae: Triatominae) vectors of Chagas disease in Mexico. Journal of Medical Entomology 40: 912–920. doi: 10.1603/0022-2585-40.6.912
[7]
Oliveira-Filho AM (1989) Cost-effectiveness analysis in Chagas disease vector's control interventions. Memorias do Instituto Oswaldo Cruz 84(Supl.IV): 409–417. doi: 10.1590/S0074-02761989000300018
[8]
Oliveira Filho AM, Melo MT, Santos CE, Faria Filho OF, Carneiro FC, et al. (2000) [Focal and total residual insecticide spraying to control Triatoma brasiliensis and Triatoma pseudomaculata in Northeast Brazil]. Cadernos de Saude Publica 16(Sup 2): 105–111.
[9]
Nakagawa J, Cordón-Rosales C, Juárez J, Itzep C, Nonami T, et al. (2003) Impact of residual spraying on Rhodnius prolixus and Triatoma dimidiata in the department of Zacapa in Guatemala. Memorias do Instituto Oswaldo Cruz 98(2): 277–281. doi: 10.1590/S0074-02762003000200019
[10]
Marcondes CB, Pinto CT (1989) Effectiveness evaluation of delatmathrin (K-othrin 50 FW), in low doses, in the control of triatomine in San Sebastiao do Umbuzeiro, Paraiba. Revista da Sociedade Brasileira de Medicina Tropical 22: 85–90. doi: 10.1590/S0037-86821989000200004
[11]
Gürtler RE, Cecere MC, Canale DM, Casta？era MB, Chuit R, et al. (1999) Monitoring house reinfestation by vectors of Chagas disease: a comparative trial of detection methods during a four-year follow-up. Acta Tropica 72(2): 213–34. doi: 10.1016/S0001-706X(98)00096-5
[12]
Gürtler RE, Canale DM, Spillmann C, Stariolo R, Salomón OD, et al. (2004) Effectiveness of residual spraying of peridomestic ecotopes with deltamethrin and permethrin on Triatoma infestans in rural western Argentina: a district-wide randomized trial. Bulletin of the World Health Organization 82: 196–206.
[13]
Gorla DE (1991) Recovery of Triatoma infestans populations after insecticide application: an experimental study. Medical and Veterinary Entomology 5: 311–324. doi: 10.1111/j.1365-2915.1991.tb00557.x
[14]
Acevedo F, Godoy E, Schofield CJ (2000) Comparison of Intervention Strategies for Control of Triatoma dimidiata in Nicaragua. Memorias do Instituto Oswaldo Cruz 95(6): 867–871. doi: 10.1590/S0074-02762000000600022
[15]
Guhl F (1999) Estado actual del control de la enfermedad de Chagas en Colombia. Medicina 59(Supl.II): 103–116.
[16]
Vallejo M, Montenegro P, Reyes PA (2002) [How much does the medical treatment of chronic Chagas cardiopathy cost? Direct costs in a cardiology hospital]. [Spanish]. Archivos de Cardiología de México 72(2): 129–37.
[17]
Schenone H (1998) Human infection by Trypanosoma cruzi in Chile: epidemiology estimates and costs of care and treatment of the chagasic patient]. [Spanish]. Boletín Chileno de Parasitología 53(1–2): 23–26.
[18]
Schofield CJ, Dias JC (1991) A cost-benefit analysis of Chagas disease control. Memorias do Instituto Oswaldo Cruz 86(3): 285–295. doi: 10.1590/S0074-02761991000300002
[19]
Akhavan D (1996) Análise de custo-efectividade do programa de controle da doen？a de Chagas no Brasil [Cost-effectiveness analysis of the Chagas disease control programme in Brasil]. Project BRA-093/15 with technical Assistance from UN: Brasilia.
[20]
Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost- Effectiveness in Health and Medicine. Oxford University Press.
[21]
Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW (1997) Methods for the economic evaluation of health care programmes. Second Edition. Oxford: Oxford University Press.
[22]
Gupta UG, Clarke RE (1996) Theory and Applications of the Delphi Technique: A Bibliography (1975–1994). Technological Forecasting and Social Change 53(2): 185–211. doi: 10.1016/s0040-1625(96)00094-7
[23]
Rycroft-Malone J (2001) Formal consensus: the development of a national clinical guideline. Quality in Health Care 10: 238–244. doi: 10.1136/qhc.0100238
[24]
Evans C (1997) The use of consensus methods and expert panels in pharmacoeconomic studies. Practical applications and methodological shortcomings. Pharmacoeconomics 12(2 Pt 1): 121–9. doi: 10.2165/00019053-199712020-00003
[25]
Ministerio de Salud de Colombia (2001) Análisis de la encuesta de hogares DANE 2000. Programa de Apoyo a la Reforma: Bogotá.
[26]
Nicholls S (2005) ？Qué se está haciendo actualmente con los pacientes chagásicos en Colombia? pp. 43–47. En: Guhl F (Eds) Memorias Primer Taller Internacional sobre Control de la Enfermedad de Chagas. Curso de Diagnóstico, Manejo y Tratamiento de la enfermedad de Chagas, in VI Reunión de la Iniciativa Andina para el control de la enfermedad de Chagas., Corcas Editores Ltda: Bogotá.
[27]
Kroeger A, Ayala C, MedinaLara A (2002) Unit costs for house spraying and bednet impregnation with residual insecticides in Colombia: a management tool for the control of vector-borne disease. Ann Trop Med Parasitol 96(4): 405–16. doi: 10.1179/000349802125001159
[28]
Basombrío MA, Schofield CJ, Rojas CL, del Rey EC, et al. (1998) A cost-benefit analysis of Chagas disease control in north-western Argentina. Transactions of the Royal Society of Tropical Medicine & Hygiene 92(2): 137–143. doi: 10.1016/S0035-9203(98)90720-9
[29]
Escobar ML (2005) Health Sector Reform in Colombia, in World Bank: Development Outreach. World Bank. http://www1.worldbank.org/devoutreach/ma？y05/article.asp?id=295.
[30]
Bitrán y Asociados, Econometría SA, ESAP (2001) Evaluación y reestructuración de los procesos, estrategias y organismos públicos y privados encargados de la afiliación, pago y recaudo de aportes al sistema: Análisis de la encuesta de hogares DANE 2000, in Tercer Informe Cuatrimestral. Ministerio de Salud de Colombia, Programa de Apoyo a la Reforma, Proyecto No. 03-99: Bogotá.
[31]
Gürtler RE, Kitron U, Cecere MC, Segura EL, Cohen JE (2007) Sustainable vector control and management of Chagas disease in the Gran Chaco, Argentina. Proc Natl Acad Sci USA 104: 16194–16199. doi: 10.1073/pnas.0700863104
[32]
Castillo-Riquelme M, Chalabi Z, Lord J, Guhl F, Campbell-Lendrum D, et al. (2008) Modelling geographic variation in the cost-effectiveness of control policies for infectious vector diseases: The example of Chagas Disease. Journal of Health Economics 27: 405–426. doi: 10.1016/j.jhealeco.2007.04.005
[33]
Chuit R, Paulone I, Wisnivesky-Colli C, Bo R, Perez AC, et al. (1992) Result of a first step toward community-based surveillance of transmission of Chagas' disease with appropriate technology in rural areas. American Journal of Tropical Medicine & Hygiene 46(4): 444–50.
